|
Company
Overview
Tranzyme
Pharma is a clinical-stage biopharmaceutical company developing
novel small molecule therapeutics for the treatment of gastrointestinal
(GI) and metabolic disorders. The Company’s candidate drugs
originate from its own discovery pipeline of proprietary compounds
and exhibit high affinity for validated and “druggable”
targets in the GI tract. Tranzyme is developing first-in-class,
mechanism-based therapeutics directed at ghrelin (responsible for
upper gut motility, appetite regulation, and energy balance) and
motilin (responsible for regulation of GI transit). The Company’s
product pipeline includes:
|
| |
• |
TZP-101
(Phase I) for acute GI motility disorders such as post-operative ileus.
TZP-101 is a ghrelin receptor agonist with potent and selective gastroprokinetic
properties that represents the first in its class to enter clinical
trials. |
|
| |
• |
TZP-102
(late-stage preclinical) a second generation oral ghrelin agonist
for chronic and acute instances of gastroparesis, an impairment of
GI motility particularly common among diabetics. TZP-102 is on track
to enter the clinic by the first quarter of 2007. |
|
| |
• |
TZP-201/202
(preclinical) motilin antagonists for diarrhea-predominant irritable
bowel syndrome and functional dyspepsia. |
|
| |
• |
TZP-301
(lead optimization) ghrelin antagonist for obesity. |
|
|
Technology
Tranzyme Pharma’s Macrocylic Template Chemistry (MATCH™)
is a particularly rich source for novel drug candidates as it maintains
the favorable characteristics exhibited by large biomolecules, such
as tight receptor binding for high potency and selectivity, while
eliminating the drawbacks associated with peptide and protein drugs,
including poor metabolic stability, low oral bioavailability, lack
of membrane permeability, high manufacturing costs, and antigenicity.
The major advantages
of MATCH include:
|
| |
•
|
Exploits
an unique compound class, macrocyclic small molecules (MW ~500), with
exceptional flexibility for interacting with multiple target types
|
|
| |
•
|
Proven
effective on major druggable target classes (GPCRs, protein kinases,
etc.) |
|
| |
•
|
Produces
orally bioavailable compounds |
|
| |
•
|
Ability
to find both agonists and antagonists |
|
| |
•
|
Produces
information-rich primary hits |
|
| |
• |
Designed
for accelerated, resource-efficient lead optimization |
|
